Phaseline

Companies › Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology; next expected readout May 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cellspan™ Esophageal Implant (CEI)
Engineered synthetic scaffold seeded with patient's adipose-derived mesenchymal stem cells
–Phase 1Esophageal DiseasesMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05877300Cellspan™ Esophageal Implant (CEI)Phase 1Esophageal DiseasesGastroenterologyMay 2029

From the company's SEC filings

Cash of $0m on 2026-06-30; operating cash outflow about $3m a year; runway about 1 months at that burn, to Aug 2026

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.